Observational Study in Patients With HIV Infection Type 1 After Switching to a Viramune®-Containing Therapy Regimen

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Observational study to collect data on maintaining anti-retroviral activity (quantitative HIV RNA determination) and immunological activity (CD4 cells) despite switching from protease inhibitor to nonnucleoside reverse transcriptase inhibitor (NNRTI) (Viramune®).

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Boehringer Ingelheim
• Treatments: Nevirapine

Criteria

Inclusion Criteria:

• Adult male or female patients with HIV type 1 infection

Exclusion Criteria:

• Counter-indications according to summary of product characteristics (SPC) for Viramune tablets

• No persons under 18

• Pregnancy and breast-feeding

• Use of oral contraceptives

• Use of drugs affecting CYP450 3A metabolism